Donate

Publication

Improving target assessment in biomedical research: the GOT-IT recommendations

Citation:
Nature Reviews Drug Discovery 2021; 20: 64–81 https://doi.org/10.1038/s41573-020-0087-3
Authored By:
Emmerich, C.H., Gamboa, L.M., Hofmann, M.C.J. Marc Bonin-Andresen, Olga Arbach, Pascal Schendel, Björn Gerlach, Katja Hempel, Anton Bespalov, Ulrich Dirnagl & Michael J. Parnham
Abstract:
Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. This transition can be facilitated by a timely focus on target assessment aspects such as target-related safety issues, druggability and assayability, as well as the potential for target modulation to achieve differentiation from established therapies. Here, we present recommendations from the GOT-IT working group, which have been designed to support academic scientists and funders of translational research in identifying and prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical development programmes. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is intended to stimulate academic scientists’ awareness of factors that make translational research more robust and efficient, and to facilitate academia–industry collaboration.
Published in:
Nature Reviews Drug Discovery
View article

More Publications

April 18, 2024

Nature Genetics

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

View
March 5, 2024

Translational Psychiatry

Potential causal association between gut microbiome and posttraumatic stress disorder

View
January 29, 2024

Scientific Reports

Differential recruitment of brain circuits during fear extinction in non-stressed compared to stress resilient animals

View
December 29, 2023

Journal of Law and the Biosciences

Defusing the legal and ethical minefield of epigenetic applications in the military, defense, and security context

View
August 1, 2023

Journal of Psychopharmacology

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

View
July 29, 2023

Frontiers in Neurology

Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders

View
View All

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

©2023 Cohen Veterans Bioscience |  Privacy Policy | Terms of Use

Newsletter